Technology
Health
Biotechnology

Ardelyx

$2.81
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.08 (2.93%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Ardelyx and other stocks, options, ETFs, and crypto commission-free!

About

Ardelyx, Inc. Common Stock, also called Ardelyx, is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. Read More It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Employees
86
Headquarters
Fremont, California
Founded
2007
Market Cap
175.91M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
330.66K
High Today
$2.86
Low Today
$2.74
Open Price
$2.74
Volume
34.04K
52 Week High
$4.70
52 Week Low
$1.60

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Financial PostMay 16

Tempest Therapeutics Starts Phase I/Ib Clinical Trial with First-in-Class PPAR Alpha Antagonist

–Company strengthens board of directors and scientific advisory board with appointments of Mike Raab and Benjamin Cravatt– SAN FRANCISCO — Tempest Therapeutics Inc., a clinical-stage biotechnology company developing a broad portfolio of first-in-class immunomodulatory small molecules targeting diverse cancers, today announced that the first patient has been dosed with TPST-1120 in a Phase I/Ib trial to treat advanced solid tumor malignancies. PPAR (peroxisome proliferator-activated receptor) alpha is a nu...

42
PR NewswireMay 7

Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights

FREMONT, Calif., May 7, 2019 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2019. "With our two ongoing Phase 3 clinical trials for tenapanor for the treatment of hyperphosphatemia in patients with ESRD on dialysis, one as a single agent therapy and the other as ...

24
Yahoo FinanceMay 7

Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?

20

Earnings

-$0.55
-$0.30
-$0.04
$0.21
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.